Form 8-K - Current report:
SEC Accession No. 0001213900-24-066613
Filing Date
2024-08-08
Accepted
2024-08-08 16:05:45
Documents
14
Period of Report
2024-08-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea021083501-8k_cadrenal.htm   iXBRL 8-K 24953
2 PRESS RELEASE, ISSUED BY CADRENAL THERAPEUTICS, INC. ON AUGUST 7, 2024 ea021083501ex99-1_cadrenal.htm EX-99.1 17207
  Complete submission text file 0001213900-24-066613.txt   222604

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cvkd-20240807.xsd EX-101.SCH 3015
4 XBRL LABEL FILE cvkd-20240807_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE cvkd-20240807_pre.xml EX-101.PRE 22359
16 EXTRACTED XBRL INSTANCE DOCUMENT ea021083501-8k_cadrenal_htm.xml XML 3801
Mailing Address 822 A1A NORTH SUITE 300 PONTE VEDRA FL 32082
Business Address 822 A1A NORTH SUITE 300 PONTE VEDRA FL 32082 904-300-0701
Cadrenal Therapeutics, Inc. (Filer) CIK: 0001937993 (see all company filings)

EIN.: 880860746 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41596 | Film No.: 241188184
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)